Fitch Revises Outlook on Jubilant Pharma to Negative, Affirms at 'BB'
Fitch Ratings has revised the outlook on Singapore-based Jubilant Pharma Limited's (JPL) Long-Term Issuer Default Rating (IDR) to Negative, from Stable, and has affirmed the IDR at 'BB'. The agency…